Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Monitoring the proportion infected by SARS-CoV-2 from age-stratified hospitalisation and serological data

View ORCID ProfileNathanaël Hozé, Juliette Paireau, Nathanaël Lapidus, Cécile Tran Kiem, View ORCID ProfileHenrik Salje, Gianluca Severi, Mathilde Touvier, Marie Zins, Xavier de Lamballerie, Daniel Lévy-Bruhl, Fabrice Carrat, Simon Cauchemez
doi: https://doi.org/10.1101/2021.01.11.21249435
Nathanaël Hozé
1Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Nathanaël Hozé
Juliette Paireau
1Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France
2Santé Publique France, French National Public Health Agency, Saint-Maurice, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nathanaël Lapidus
3Sorbonne Université, Inserm, Institut Pierre-Louis d’Epidémiologie et de Santé Publique, Paris, France
4Département de Santé Publique, APHP. Sorbonne Université, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cécile Tran Kiem
1Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France
5Collège Doctoral, Sorbonne Université, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henrik Salje
1Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France
6Department of Genetics, University of Cambridge, Cambridge, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Henrik Salje
Gianluca Severi
7CESP UMR1018, Université Paris-Saclay, UVSQ, Inserm, Gustave Roussy, Villejuif, France
8Department of Statistics, Computer Science and Applications, University of Florence, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mathilde Touvier
9Sorbonne Paris Nord University, Inserm U1153, Inrae U1125, Cnam, Nutritional Epidemiology Research Team (EREN), Epidemiology and Statistics Research Center – University of Paris (CRESS), Bobigny, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie Zins
10Paris University, Paris, France
11Paris Saclay University, Inserm UMS 11 Villejuif, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xavier de Lamballerie
12Unité des Virus Emergents, UVE: Aix Marseille Univ, IRD 190, INSERM 1207, IHU Méditerranée Infection, 13005, Marseille, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Lévy-Bruhl
2Santé Publique France, French National Public Health Agency, Saint-Maurice, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Fabrice Carrat
3Sorbonne Université, Inserm, Institut Pierre-Louis d’Epidémiologie et de Santé Publique, Paris, France
4Département de Santé Publique, APHP. Sorbonne Université, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Simon Cauchemez
1Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, UMR2000, CNRS, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: simon.cauchemez@pasteur.fr
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Regional monitoring of the proportion infected by SARS-CoV-2 is important to guide local management of the epidemic, but is difficult in the absence of regular nationwide serosurveys.

Methods We developed a method to reconstruct in real-time the proportion infected by SARS-CoV-2 and the proportion of infections being detected from the joint analysis of age-stratified seroprevalence, hospitalisation and case data. We applied our approach to the 13 French metropolitan regions.

Findings We estimate that 5.7% [5.1%-6.4%] of adults in metropolitan France had been infected by SARS-CoV-2 by May 2020. This proportion remained stable until August and increased to 12.6% [11.2%-14.3%] by the end of November. With 23.8% [21.2%-26.8%] infected in the Paris region compared to 4.0% [3.5% - 4.6%] in Brittany, regional variations remained large (Coefficient of Variation CV: 0.53) although less so than in May (CV: 0.74). The proportion infected was twice higher (17.6% [13.4%-22.7%]) in 20-49 y.o. than in 50+ y.o (8.0% [5.7% - 11.5%]). Forty percent [33.7% - 45.4%] of infections in adults were detected in June-August compared to 55.7% [48.7% - 63.1%] in September-November. Our method correctly predicted seroprevalence in 11 regions in which only hospitalisation data were used.

Interpretation In the absence of contemporary serosurvey, our real-time monitoring indicates that the proportion infected by SARS-CoV-2 may be above 20% in some French regions.

Funding EU RECOVER, ANR, Fondation pour la Recherche Médicale, Inserm.

Competing Interest Statement

Prof Fabrice Carrat reports personal fees from Imaxio and Sanofi, outside the submitted work. The other authors declare no competing interests.

Funding Statement

Support for this study was provided by ANR (Agence Nationale de la Recherche, #ANR-20-COVI-000, #ANR-10-COHO-06), Fondation pour la Recherche Medicale (#20RR052-00), Inserm (Institut National de la Sante et de la Recherche Medicale, #C20-26). We acknowledge financial support from the Investissement d Avenir program, the Laboratoire d Excellence Integrative Biology of Emerging Infectious Diseases program (grant ANR-10-LABX-62-IBEID), Sante Publique France, the INCEPTION project (PIA/ANR-16-CONV-0005), and the European Union Horizon 2020 research and innovation program under grants 101003589 (RECOVER) and 874735 (VEO), AXA. The CONSTANCES Cohort Study is supported by the Caisse Nationale d Assurance Maladie (CNAM), the French Ministry of Health, the Ministry of Research, the Institut national de la sante et de la recherche medicale. CONSTANCES benefits from a grant from the French National Research Agency [grant number ANR-11-INBS-0002] and is also partly funded by MSD, AstraZeneca, Lundbeck and L Oreal. The E3N-E4N cohort is supported by the following institutions: Ministere de lEnseignement Superieur, de la Recherche et de l Innovation, INSERM, University Paris-Saclay, Gustave Roussy, the MGEN, and the French League Against Cancer. The NutriNet-Sante study is supported by the following public institutions: Ministere de la Sante, Sante Publique France, Institut National de la Sante et de la Recherche Medicale (INSERM), Institut National de la Recherche Agronomique (INRAE), Conservatoire National des Arts et Metiers (CNAM) and Sorbonne Paris Nord.The CEPH-Biobank is supported by the Ministere de l Enseignement Superieur, de la Recherche et de l Innovation.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

NA

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

NA

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted January 13, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Monitoring the proportion infected by SARS-CoV-2 from age-stratified hospitalisation and serological data
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Monitoring the proportion infected by SARS-CoV-2 from age-stratified hospitalisation and serological data
Nathanaël Hozé, Juliette Paireau, Nathanaël Lapidus, Cécile Tran Kiem, Henrik Salje, Gianluca Severi, Mathilde Touvier, Marie Zins, Xavier de Lamballerie, Daniel Lévy-Bruhl, Fabrice Carrat, Simon Cauchemez
medRxiv 2021.01.11.21249435; doi: https://doi.org/10.1101/2021.01.11.21249435
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Monitoring the proportion infected by SARS-CoV-2 from age-stratified hospitalisation and serological data
Nathanaël Hozé, Juliette Paireau, Nathanaël Lapidus, Cécile Tran Kiem, Henrik Salje, Gianluca Severi, Mathilde Touvier, Marie Zins, Xavier de Lamballerie, Daniel Lévy-Bruhl, Fabrice Carrat, Simon Cauchemez
medRxiv 2021.01.11.21249435; doi: https://doi.org/10.1101/2021.01.11.21249435

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (51)
  • Cardiovascular Medicine (453)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (158)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5275)
  • Forensic Medicine (3)
  • Gastroenterology (197)
  • Genetic and Genomic Medicine (759)
  • Geriatric Medicine (80)
  • Health Economics (213)
  • Health Informatics (700)
  • Health Policy (361)
  • Health Systems and Quality Improvement (224)
  • Hematology (99)
  • HIV/AIDS (164)
  • Infectious Diseases (except HIV/AIDS) (5904)
  • Intensive Care and Critical Care Medicine (363)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (769)
  • Nursing (43)
  • Nutrition (132)
  • Obstetrics and Gynecology (144)
  • Occupational and Environmental Health (234)
  • Oncology (481)
  • Ophthalmology (152)
  • Orthopedics (39)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (99)
  • Psychiatry and Clinical Psychology (865)
  • Public and Global Health (2028)
  • Radiology and Imaging (351)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (287)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)